Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
| Business Activity | PASS |
| Debt Ratio (0.08%) | PASS |
| Cash Ratio (0.60%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-13 | -0.23 | Pending | -- |
| 2026-05-13 | -0.39 | -0.30 | +23.7% |
| 2026-03-17 | -0.37 | -0.37 | +2.1% |
| 2025-11-12 | -0.34 | -0.11 | +68.5% |
| 2025-08-14 | -0.39 | -0.47 | -19.0% |
| 2025-05-15 | -0.35 | -0.24 | +32.2% |
| 2025-03-20 | -0.34 | -0.32 | +8.0% |
| 2024-11-14 | -0.39 | -0.63 | -63.2% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8.7M | -$17.1M | -$15.4M | $6.0M | -$23.0M | -0.30 |
| 2025-12-31 | $5.4M | -$20.5M | -$18.7M | $2.6M | -$22.9M | — |
| 2025-09-30 | — | -$5.2M | -$18.6M | -$488.0K | -$24.0M | -0.10 |
| 2025-06-30 | $400.0K | $108.8M | $126.1M | $300.0K | -$22.8M | 2.07 |
| 2025-03-31 | — | -$12.0M | -$10.2M | — | -$19.7M | -0.24 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-15 | CROMBEZ ERIC M.D. | Director | 26,143 | $144.6K |
| 2026-04-01 | GOLDAN KEITH ALAN | Director | 32,751 | -- |
| 2026-03-31 | SESHADRI VISHWAS | Chief Executive Officer | 29,985 | $131.5K |
| 2026-03-16 | VAZZANO JOSEPH WALTER | Chief Financial Officer | 785 | $3.7K |
| 2026-02-02 | ALVINO MARK J. | Director | 2,000 | $10.2K |
| 2026-02-02 | CROMBEZ ERIC M.D. | Director | 16,284 | $82.9K |
| 2026-02-02 | SILVERSTEIN CHRISTINE BERNI | Director | 20,070 | $102.2K |
| 2026-02-02 | ALLAND LEILA | Director | 18,065 | $92.0K |
| 2026-02-02 | WUCHTERL DONALD A | Director | 14,814 | $75.4K |
| 2026-01-26 | ALLAND LEILA | Director | 37,313 | -- |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Nantahala Capital Management, LLC | 5.0M | $27.3M | 0.1% |
| Blackrock Inc. | 3.2M | $17.4M | 0.1% |
| AIGH Capital Management LLC | 3.1M | $16.9M | 0.1% |
| Cable Car Capital, LP | 3.0M | $16.4M | 0.1% |
| Suvretta Capital Management, LLC | 2.7M | $14.6M | 0.0% |
| Vanguard Capital Management LLC | 2.2M | $11.8M | 0.0% |
| Propel Bio Management, LLC | 1.3M | $7.2M | 0.0% |
| Kennedy Capital Management, LLC | 1.3M | $6.9M | 0.0% |
| Geode Capital Management, LLC | 1.2M | $6.6M | 0.0% |
| Goldman Sachs Group Inc | 1.1M | $6.2M | 0.0% |
$165.0M
2.13
1.339
7
$14.5M
$23.2M
1.00
16.87
0.3%
226
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.23 | Pending | — |
| 2026-05-13 | $-0.39 | $-0.30 | +23.7% |
| 2026-03-17 | $-0.37 | $-0.37 | +2.1% |
| 2025-11-12 | $-0.34 | $-0.11 | +68.5% |
| 2025-08-14 | $-0.39 | $-0.47 | -19.0% |
| 2025-05-15 | $-0.35 | $-0.24 | +32.2% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($19.71, 7 analysts) | |||
| 10 | $56.10 | +$141.00 (251%) | 16.8R |
| 50 | $280.50 | +$705.00 (251%) | 16.8R |
| 100 | $561.00 | +$1,410.00 (251%) | 16.8R |
| To Fair Value ($3.60) | |||
| 10 | $56.10 | +$-20.10 (-36%) | -2.4R |
| 50 | $280.50 | +$-100.50 (-36%) | -2.4R |
| 100 | $561.00 | +$-201.00 (-36%) | -2.4R |
- Elevated short interest (16.87 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| BETA | 0.423 |
| HQH | 0.398 |
| SYRE | 0.387 |
| AURA | 0.387 |
| IMTX | 0.384 |
| Ticker | Correlation |
|---|---|
| ZAIN.KW | -0.188 |
| UNIKAI.AE | -0.170 |
| ALIMTIAZ.KW | -0.132 |
| NISUY | -0.121 |
| 2801.T | -0.121 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.